38157030|t|Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease.
38157030|a|BACKGROUND: Neuronal pentraxin-2 (NPTX2), crucial for synaptic functioning, declines in cerebrospinal fluid (CSF) as cognition deteriorates. The variations of CSF NPTX2 across mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and its association with brain metabolism remain elusive, albeit relevant for patient stratification and pathophysiological insights. METHODS: We retrospectively analyzed 49 MCI-AD patients grouped by time until dementia (EMCI, n = 34 progressing within 2 years; LMCI, n = 15 progressing later/stable at follow-up). We analyzed demographic variables, cognitive status (MMSE score), and CSF NPTX2 levels using a commercial ELISA assay in EMCI, LMCI, and a control group of age-/sex-matched individuals with other non-dementing disorders (OND). Using [18F]FDG PET scans for voxel-based analysis, we explored correlations between regional brain metabolism metrics and CSF NPTX2 levels in MCI-AD patients, accounting for age. RESULTS: Baseline and follow-up MMSE scores were lower in LMCI than EMCI (p value = 0.006 and p < 0.001). EMCI exhibited significantly higher CSF NPTX2 values than both LMCI (p = 0.028) and OND (p = 0.006). We found a significant positive correlation between NPTX2 values and metabolism of bilateral precuneus in MCI-AD patients (p < 0.005 at voxel level, p < 0.05 with family-wise error correction at the cluster level). CONCLUSIONS: Higher CSF NPTX2 in EMCI compared to controls and LMCI suggests compensatory synaptic responses to initial AD pathology. Disease progression sees these mechanisms overwhelmed, lowering CSF NPTX2 approaching dementia. Positive CSF NPTX2 correlation with precuneus glucose metabolism links to AD-related metabolic changes across MCI course. These findings posit CSF NPTX2 as a promising biomarker for both AD staging and progression risk stratification.
38157030	20	25	NPTX2	Gene	4885
38157030	102	122	cognitive impairment	Disease	MESH:D003072
38157030	130	149	Alzheimer's disease	Disease	MESH:D000544
38157030	163	183	Neuronal pentraxin-2	Gene	4885
38157030	185	190	NPTX2	Gene	4885
38157030	314	319	NPTX2	Gene	4885
38157030	332	352	cognitive impairment	Disease	MESH:D003072
38157030	354	357	MCI	Disease	MESH:D060825
38157030	366	385	Alzheimer's disease	Disease	MESH:D000544
38157030	387	389	AD	Disease	MESH:D000544
38157030	469	476	patient	Species	9606
38157030	565	568	MCI	Disease	MESH:D060825
38157030	569	571	AD	Disease	MESH:D000544
38157030	572	580	patients	Species	9606
38157030	603	611	dementia	Disease	MESH:D003704
38157030	613	617	EMCI	Disease	
38157030	781	786	NPTX2	Gene	4885
38157030	828	832	EMCI	Disease	
38157030	903	926	non-dementing disorders	Disease	MESH:C580335
38157030	928	931	OND	Disease	MESH:C535332
38157030	940	948	[18F]FDG	Chemical	MESH:D019788
38157030	1060	1065	NPTX2	Gene	4885
38157030	1076	1079	MCI	Disease	MESH:D060825
38157030	1080	1082	AD	Disease	MESH:D000544
38157030	1083	1091	patients	Species	9606
38157030	1181	1185	EMCI	Disease	
38157030	1219	1223	EMCI	Disease	
38157030	1259	1264	NPTX2	Gene	4885
38157030	1303	1306	OND	Disease	MESH:C535332
38157030	1372	1377	NPTX2	Gene	4885
38157030	1426	1429	MCI	Disease	MESH:D060825
38157030	1430	1432	AD	Disease	MESH:D000544
38157030	1433	1441	patients	Species	9606
38157030	1559	1564	NPTX2	Gene	4885
38157030	1568	1572	EMCI	Disease	
38157030	1655	1657	AD	Disease	MESH:D000544
38157030	1737	1742	NPTX2	Gene	4885
38157030	1755	1763	dementia	Disease	MESH:D003704
38157030	1778	1783	NPTX2	Gene	4885
38157030	1811	1818	glucose	Chemical	MESH:D005947
38157030	1839	1841	AD	Disease	MESH:D000544
38157030	1875	1878	MCI	Disease	MESH:D060825
38157030	1912	1917	NPTX2	Gene	4885
38157030	1952	1954	AD	Disease	MESH:D000544
38157030	Association	MESH:D000544	4885

